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Effect of Zelnate administered as a metaphylactic upon initial processing of high-risk,
newly received beef calves on performance and morbidity
Brady E. Martin1, Reagan N. Cauble1, Elizabeth B. Kegley1, and Jeremy G. Powell1
1

University of Arkansas Division of Agriculture, Fayetteville, AR, 72701

Abstract
Bovine respiratory disease (BRD) is the most prominent and costly ailment in the stocker
cattle industry today, and its prevalence has not been diminished in the last thirty years.
Therefore, the objective of this study was to investigate the effects of Zelnate, a DNA
immunostimulant, administered upon arrival to calves (n = 261; initial body weight 253 ± 4.0
kg), on morbidity and mortality, growth performance, and producer costs. Crossbred male beef
calves were acquired and transported to the University of Arkansas stocker unit for a 42-d
backgrounding period. Calves were allocated into two treatment groups: 1) Zelnate, DNA
immunostimulant administered or 2) Control, in which no immunostimulant was administered.
Animals were checked daily for signs of morbidity and treated. Records for growth performance,
morbidity, and mortality were kept. Data were analyzed using the GLIMMIX procedures of
SAS. Significance was declared at P < 0.05 and tendencies between 0.05 ≤ P < 0.10. Zelnate
treated calves tended (P = 0.09) to have a lower relapse rate compared to control calves. Average
daily gain was similar (P = 0.60) between the two treatment groups. The treatment cost for the
Zelnate group was more expensive than the cost to treat the control group (P < 0.01). Overall,
our findings indicate that Zelnate administered upon arrival to high risk calves did not improve
morbidity rates nor reduce the need for antibiotic treatment for respiratory disease, or affect
performance, however it tended to decrease relapse rate and did increase costs by $9.24 per calf.
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Based upon these results, Zelnate does not appear to be an effective metaphylactic therapy for
BRD in newly received cattle.
Introduction and Literature Review
Physiological stress, commingling in sale barns, and numerous viral and bacterial
pathogens are responsible for bovine respiratory disease (BRD), and it remains the leading cause
of feedlot morbidity and mortality (Woolums et al., 2005). The economic losses the industry
endures annually is upwards of $750 million (Griffin, 1997) and disease prevalence has remained
unchanged for the last three decades (Miles, 2009). The portion of costs from BRD due to the
combination of mortality and treatment costs is approximately 82% (Faber et al., 2000). Each
individual treatment of this disease costs on average $23.60, for both small feedlot operations
(1,000-7,999 head) and large feedlot operations (8,000 or more head) there was not a statistical
difference in cost per case. This cost per case has nearly doubled since 1999 when it cost on average
$12.59 to treat per case (USDA-APHIS, 2013). This is a troubling indication that BRD is trending
upwards in cost quite rapidly. Part of this increase in cost isn’t solely medical treatment but also
due to loss of value of the livestock form poorer feed efficiency, less average gain, and lower meat
grade (Griffin, 1997). In the beef industry the reduced daily live weight gains from BRD means a
longer finishing time, leading to increased production costs (Potter, 2015).
Stocker-feedlot facilities are complex systems with small profit margins and cattle health
affects every aspect of their day to day operation. The ability to effectively manage cattle health
affects optimization of available pens and pastures, management of labor and facilities,
performance of cattle, and ultimately profits (Sweiger, 2010). The direct costs of BRD alone
highlight the reason why feedlot operator’s management strategies are frequently directed at
minimizing the occurrence of this disease in their cattle (USDA-APHIS, 2013). However, despite
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advances in veterinary medicine, animal husbandry, and animal welfare, BRD continues to be a
major problem for producers (Gorden, 2010). Stressors from handling, weaning, commingling,
transporting, and changes in environment and diet contribute substantially to the probability of an
animal contracting BRD by suppressing the animal’s immune system.
BRD is of multifactorial origin, onset of this disease depends on complex interactions
between viruses, bacteria, the environment and the host (Faber et al., 2000). Most animals with
healthy immune systems can fight off the initial viral infections, thus avoiding severe disease.
However, cattle with immune suppression due to stress factors are not able to combat the initial
viral infection (Powell, 2010) The usual scenario leading to the development of the disease
involves the combination of an immunocompromised calf (usually due to stress), exposed to an
immunosuppressive viral agent such as bovine virus diarrhea virus or bovine herpesvirus-1
(infectious bovine rhinotracheitis virus). The establishment of a primary viral infection leads to
the progressive development of BRD from the upper to the lower respiratory tract. This viral
immunosuppression compromises the innate immune system and mucociliary escalator. This
condition allows commensal bacterial pathogens to migrate and colonize the lower respiratory
tract, leading to pulmonary compromise, inflammation, and gross pathology (Edwards, 2010). The
main pathogenic bacteria responsible for colonization and replication inside the lower respiratory
tract include Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni (Potter,
2015).
The early clinical signs commonly associated with BRD are nasal discharge, decreased
appetite, lethargy, separation form the herd, a gaunt appearance, an increased respiratory rate and
coughing. Animals often also have a rectal temperature of greater than 40.0 degrees Celsius and
occasionally sores on the mouth and/or nose (Powell, 2010). Once an animal is infected with BRD
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the immune system’s nutrient consumption increases dramatically. Rates of gluconeogenesis
increase 150% to 200% during moderate infections, and the basal metabolic rate has been shown
to increase 25% to 55% during periods of sepsis (Gorden & Plummer, 2010). If treatment of this
disease is delayed, the number of deaths or chronically infected animals in the herd will likely
increase. As it progresses, severe lung damage occurs from inflammation due to infection. Often,
the lung damage caused by BRD is irreversible (Powell, 2010). Mortality rate of calves diagnosed
and treated for BRD was 5.9% compared to .35% for those calves not diagnosed with BRD (Faber
et al., 2000). Enteritis is the most common cause of death in BRD infected cattle, followed by
pneumonia. Once an animal contracted enteritis or pneumonia the case fatality rate averaged
11.18% and 17.9% respectively (Silva et al., 1996).
A compounding difficulty in the process of successfully diagnosing BRD is it is quite
difficult to accurately diagnose due to the nature of the disease and the nature of cattle themselves.
Being a prey animal, cattle instinctively mask the clinical signs of sickness as a means of selfpreservation. For this reason, subclinical disease is difficult, if not impossible, to identify. Based
on the usual subjective methods of first identifying BRD, identifying sick cattle is sometimes
considered a learned skill or an art (Edwards, 2010). The difficulty accurately identifying all
animals that require treatment is the reason many clinicians put a greater emphasis on prevention
of BRD instead of treating the disease post-infection (Griffin, 1997). In fact, treatment of BRD
post-infection may be inadequate to prevent significant production loses. One study found that
almost 70% of cattle never treated for BRD had pulmonary lesions at slaughter that were indicative
of the disease, indicating many infected cattle were never identified. If this finding is representative
of the general cattle population, then the use of clinical signs as indicators of disease could be
resulting in a large misclassification bias (Wittum 1996). These cattle were likely infected with a

ZELNATE AS METAPHYLACTIC THERAPY IN HIGH-RISK CALVES

7

less obvious subclinical infection of BRD, which leads to performance effects that have a similar
devastating economic impact as the more easily recognizable clinical infection. The imprecision
of clinical diagnosis of BRD strengthens the argument for mass medications, particularly when
significant morbidity in a group is anticipated (Sweiger & Nichols, 2010).
A way to avoid the current increasing resistance of BRD inducing bacteria while treating
subclinical animals is by improving the active immune system of cattle by administering herdwide vaccines. However, these vaccines often cause tissue injury and an inflammatory response at
the injection site and reduced feed consumption upon successive vaccinations. These reactions
lead to decreased carcass value due to having to remove inflamed or damaged tissue as waste and
decreased gain to feed ratio that increases feed expenses for the producer. This issue of multiple
vaccinations compounding these effects is profound in the stocker industry due to the lack of
communication of specific vaccination schedules between locations, in fact some cattle may
receive as many as six vaccinations during their life time, resulting in intense local reactions at the
site of injection (Stokka et al., 1994). Nonetheless it must be acknowledged that this unknown
history is not only a complicating and determining factor in cattle health but also an opportunity
for the next owner of these calves to procure them at a discounted price relative to the market.
These discounted prices are a major driver in profitability for producers in this segment of the
industry (Sweiger & Nichols, 2010). Even when vaccines don’t damage carcass traits or feeding
behavior, many pathogens and immune responses to these pathogens have been poorly
characterized. As a result, it is difficult to develop effective vaccines to combat these pathogens
(Babiuk, 2002).
Other anti-infectives such as corticosteroids and non-steroidal anti-inflammatory drugs
(NSAIDs) have been used as attempted treatments for BRD besides vaccines and antibiotics to
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little avail. There is insufficient data to conclude a potential positive effect of NSAID use on the
positive cost benefits of NSAIDs as treatments of BRD (Potter, 2015). The lack of effective
treatments that do not cause rates of antibiotic resistance to increase has caused researchers to
recommend future projects that examine the effectiveness of new types of vaccines that do not
trigger similar immune responses as clostridial vaccines (Johnson, 2016).
One possible novel solution that falls in line with these recommendations is use of the
recently released DNA immunostimulant Zelnate (Bayer HealthCare LLC, Shawnee Mission, KS)
that has resulted in decreased lung lesion scores in cattle exposed to the Mannheimia haemolytica
bacteria (Nickell et al., 2016) and a reduction of clinical signs of BRD in high-risk cattle upon
feedlot entry (Rogers et al., 2016). This pharmaceutical is intended to counteract the
immunosuppressant effects of stress on stocker calves by stimulating the subjects’ innate immune
system through exposing it to a liposome containing a non-specific DNA antigen that prepares the
calf’s body to fight off a Mannheimia haemolytica infection.
The principle upon which polynucleotide immunostimulants like Zelnate are based is that
the liposome is taken up by a cell, and if the appropriate promoters/enhancers are present, the genes
encoded in the liposome are expressed and are translated to produce the encoded protein. Since
these proteins are foreign, they induce an immune response in the animal. The great advantage of
this approach, especially for viral antigens, is that the antigen is expressed endogenously and,
therefore, all the posttranslational modifications are similar to those present during infection. As a
result, the antigens are authentic, with all the conformational epitopes required for protection being
expressed. To assist in elevating the immune response, the liposome contains built-in adjuvants in
the form of CpG sequences. These sequences are critical in not only creating the cytokine microenvironment required for induction of immunity, but also in providing the Th1±Th2 balance and
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the long-term memory observed with DNA-based immunostimulants. A real advantage of DNA
immunostimulants such as Zelnate is that they can induce immune responses in neonates even in
the presence of passive antibody. This is a true advantage over conventional or genetically
engineered vaccines. This observation is extremely encouraging since it will allow us to administer
to animals at a very early age, a time when they are easy to handle, and this will ensure that they
are fully protected at the time passive antibody decays (Babiuk, 2002). Also, the concern regarding
typical vaccines negatively affecting growth performance or feeding behavior does not occur with
Zelnate (Gaspers, 2016). This novel pharmaceutical has also been proven to be inactive on human
and mouse toll-like receptor 9 in cell culture in both recombinant and natural cellular receptor
settings despite the presence of numerous non-methylated CpG motifs in its plasmid DNA
(Babiuk, 2002).
Zelnate is designed to reduce the clinical instances of BRD and reduce the use of antibiotics
while improving performance in high-risk, newly received beef calves. The objective of the current
study is to evaluate the effect of metaphylactic administration of Zelnate on morbidity, mortality,
and growth performance in newly received high-risk calves during a 42-d receiving period. The
majority of calves treated for BRD are treated within the first 27 d of the feeding period (Buhman
et al., 2000).

Materials and Methods
Animals
Crossbred male beef calves (n = 261; bulls = 129; steers = 132, initial body weight (BW)
= 253 ± 4.0 kg) acquired from multiple local auction markets were shipped to the University of
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Arkansas, Division of Agriculture, Stocker and Receiving Cattle Unit located near Fayetteville,
AR. Calves were received on 3 separate dates (blocks) with 98, 82, and 81 calves arriving each of
these days, respectively. For each arrival date, 4 pens were assigned randomly per treatment.
Treatment pens were separated such that cattle on different treatments were not housed with fenceline contact. Prior to study initiation, animal care and use procedures were approved by the
University of Arkansas Care and Use Committee (approval #19018).
Allocation and Arrival Procedures
Upon arrival on d 0, calves were weighed, assigned a unique ear tag for identification,
tested for the prevalence of persistent infection with bovine viral diarrhea virus (PI-BVDV), and
arrival castrate status was determined. No calves tested positive for PI-BVDV. Calves were
stratified chute side by arrival castrate status using random allotment sheets so that cattle that
arrived as steers and bulls were evenly distributed within pen across both treatments (8 pens/block;
10 to 13 calves/pen) and pens were assigned randomly to 1 of 2 experimental treatments: 1)
Zelnate, DNA immunostimulant metaphylactic administration (Zelnate, 2 mL intramuscularly
(IM); Bayer HealthCare, Shawnee Mission, KS), 2) Control, in which calves received no
immunostimulant.
On d 0, calves were administered the appropriate experimental treatment, and all calves
received a pentavalent modified-live virus vaccine for respiratory pathogens Titanium 5, Elanco
Animal Health, Greenfield, IN), a clostridial-tetanus toxoid (Covexin 8, Merck Animal Health,
Madison, NJ), and an injectable anthelmintic (Cydectin Injectable, Bayer HealthCare LLC).
Calves were branded on the right hip and intact males were castrated via banding (California
Bander, InoSol Co. LLC, El Centro, CA). Blood was also drawn through jugular venipuncture into
vacuum tubes with a clot activated gel. Blood was centrifuged and serum stored at -20° C until
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analyzed. Serum analysis of haptoglobin concentrations from d 0 and 14 were conducted using
ELISA panels (Immunology Consultants Laboratory, Inc. ). Calves were revaccinated on d 14 with
the same pentavalent modified-live virus respiratory vaccine and clostridial-vaccine.
Housing and Diets
Calves were moved to their assigned 0.4-ha pens and provided 0.45 kg/d (as-fed basis) of
a receiving supplement which was increased to 1.8 kg/d and provided 160 mg monensin after diet
adaptation. Supplement was offered daily at 0800 and calves had ad libitum access to
bermudagrass hay and water.
Procedures
Body weights were measured on d 0, 14, 28, 41, and 42. Average daily gain was determined
based on initial BW, two interim BW, and the average of the final 2 BW (d 41 and 42).
Assessment and Treatment of Morbid Calves
During feeding, a pen rider blinded to experimental treatments observed cattle daily for
signs of morbidity and a Clinical Attitude Score (CAS; 0 [normal] to 5 [moribund]; Table 1) was
recorded. Calves that scored a 1 or greater were pulled, weighed, and rectal temperatures were
recorded via digital thermometer (Model No. M216, GLA Agricultural Electronics; San Luis
Obispo, CA), if temperature exceeded 40.0° C calves were treated according to a preplanned
protocol. Animals with a CAS > 2 were treated regardless of rectal temperature. All calves
qualifying for first-line BRD therapy were given enrofloxacin (Baytril 100, 5.7 mL/45 kg BW
subcutaneously (SQ); Bayer HealthCare, LLC). Enrofloxacin was followed by a 2 d post-treatment
interval (PTI) and if criteria for BRD persisted including CAS score and/or rectal temperature,
florfenicol (Nuflor, 6.0 mL/45 kg BW SQ; Merck Animal Health) was the second antibiotic
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administered. Following a 2 d PTI for florfenicol, calves eligible for a third antibiotic per
previously stated criteria were administered ceftiofur hydrochloride (Excenel, 2.0 mL/45.5 kg BW
SQ; Zoetis, Parsippany, NJ).
Morbidity data recorded included treatment date, rectal temperature at time of treatment,
incidence of first, second, or third clinical respiratory disease, treatment cost, and mortality. Calves
that were treated were housed in designated pens until deemed healthy upon the 48 h recheck.
Relapse was defined as: of those calves treated with the first antibiotic, the percentage of calves
that were treated with a second antibiotic. No animals died during the study.
Statistical Analyses
Performance data, morbidity response variables, and cost analysis were analyzed using the
GLIMMIX procedure of SAS (SAS Inst. Inc., Cary, NC). Pen served as the experimental unit for
all variables while calf served as the observational unit. The lone fixed effect in the model was
treatment and block (arrival date) was considered to be the lone random effect. Least squares
means were separated via the PDIFF option. Statistical significance was declared at P ≤ 0.05, and
tendencies at 0.05 < P ≤ 0.10.
Results and Discussion
Growth Performance
Body weight was not affected by DNA immunostimulant inclusion at processing (Table 2;
P ≥ 0.89). Initial BW were similar between control (252.2 kg) and Zelnate (252.7 kg; P = 0.93)
treated calves. Body weights on d 14 were not different regardless of treatment (P = 0.89). Day 28
BW were similar between treatment as control cattle were 278.6 kg and Zelnate cattle were 278.3
kg, respectively (P = 0.95). Final BW did not differ by treatment with control and Zelnate cattle
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weighing 294.1 and 293.5 kg (P = 0.91), respectively. Results were similar to findings by Gasper
et al. (2016) which investigated the differences in 1) saline, and 2) MLV vaccine in combination
with Mannheimia haemolytica, 3) Zelnate, and 4) MLV in combination with Mannheimia
haemolytica and Zelnate and concluded that there were no differences in final BW or ADG across
treatments. The addition of Zelnate did not affect BW.
Similarly, to growth performance, average daily gain (ADG) for the 42-d backgrounding
period was not affected by the inclusion of a DNA immunostimulant (Table 2; P ≥ 0.32). From d
0 to 14, ADG was 0.88 and 0.79 for control and Zelnate cattle respectively (P = 0.32). Average
daily gain from d 14 to 28 was unaffected by treatment (P = 0.76). Similar ADG between
treatments was observed from d 28 to 42 (P = 0.67). Overall ADG over the 42 study was not
different between control cattle (1.00 kg/d) and Zelnate cattle (0.97 kg/d; P = 0.60). Zelnate did
not have an effect on growth performance in newly received, high risk calves. A study
investigating the effects of Zelnate compared to a saline control over a 70-d backgrounding period
(Woolums et el., 2019) also reported no advantage in ADG.
Morbidity
There were no chronically ill calves or mortalities in either treatment group. Percentage
BRD morbidity for first treatment antibiotic (enrofloxacin) was similar between calves treated with
the immunostimulant (56.5 %) and control calves (49.9 %; P = 0.31; Table 3) with days in which
the first treatment was administered being similar (P = 0.72; Table 3). The percentages of calves
treated with a second antibiotic (florfenicol) did not differ between treatments (P = 0.37) with days
till second treatment occurring on day 13.2 and 12.9 for control and Zelnate calves, respectively
(P = 0.91). Days until third treatment were similar (P = 0.41). Relapse percentage accounted for
calves that were treated with a second antibiotic after being treated with the first treatment
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antibiotic. The percentage of calves that relapsed tended to differ between treatments with 47.4
and 32.2% for control and Zelnate calves, respectively (P = 0.09).
Serum haptoglobin levels for both groups on d 0 (P = 0.40) and d 14 (P = 0.99) were
similar. Rectal temperature was similar between control and Zelnate for calves treated for clinical
BRD (Table 4; P ≥ 0.13). Regardless of first (P = 0.74), second (P = 0.13), or third (P = 0.71)
antibiotic use, the inclusion of a DNA immunostimulant did not impact rectal temperatures for
calves treated for BRD. Treating high risk calves upon arrival with Zelnate did not have an effect
on morbidity variables.
Economics
The cost of antibiotic treatments were analyzed. The cost of antibiotics including all 3
treatment antibiotics used to treat clinical BRD was similar between control ($13.12) and Zelnate
cattle ($12.40) for the 42-d study (Table 4; P = 0.72). Overall costs including antibiotic costs and
the cost to treat with Zelnate upon arrival were greater ($22.36) compared to the antibiotic costs
to treat control calves ($13.12; P < 0.01).
Conclusions
The inclusion of Zelnate upon arrival had no impact on growth performance or the number
of calves treated for BRD. During the 42-d backgrounding period, there were no differences in
BW or ADG at any of the 14-d collection intervals. The percentage of calves treated for clinical
signs of BRD with one or two antibiotics did not differ and calves on both treatments had similar
days till antibiotic treatment. The cost to treat clinical signs of BRD were similar between control
and Zelnate calves, however, when the cost Zelnate was incorporated, therapeutic costs became
more expensive. In this study, the use of Zelnate as a metaphylactic treatment may have a limited
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impact on performance and morbidity in high-risk, newly received calves for the 42-d period, at
an increased cost to producers. There was a trend for a reduction in relapses and it is unknown
whether there would be improved immunity when stocker calves are moved to the feedlot.
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Table 1. Clinical attitude score system used to diagnose bovine respiratory disease.
CAS

Diagnosis

Clinical signs

0

Normal

No BRD clinical signs; calf is bright, alert and responsive when
approached.

1

Mild BRD

Calf looks ill with BRD until approached; calf brightens, moves readily,
and appears normal when approached. Calf may be mildly depressed and
small amount of nasal and/or ocular discharge may be present.

2

Moderate BRD

Calf is obviously ill with BRD; when approached calf does not brighten
up and moves slowly. Calf is moderately depressed and may exhibit
dyspnea, considerable nasal and/or ocular discharge and coughing.

3

Severe BRD

Calf is severely ill with BRD; when approached calf stumbles or moves
only with extreme coercion. Calf is severely depressed and may be
anorexic and coughing with copious nasal discharge.

4

Moribund

Calf is moribund; recumbent and not able or willing to rise or get feed and
water.

19

ZELNATE AS METAPHYLACTIC THERAPY IN HIGH-RISK CALVES
Table 2: Effect of Zelnate on growth performance in high-risk, newly received beef calves.
Treatment
Item
Control
Zelnate
SEM
Body weight, kg
Initial1
252.2
252.7
4.0
D 14
264.4
263.7
3.7
D 28
278.6
278.3
3.6
Final2
294.1
293.5
3.6
Average daily gain, kg
D 0 to 14
0.88
0.79
0.07
D 14 to 28
1.02
1.04
0.06
D 28 to 42
1.10
1.14
0.08
Overall
1.00
0.97
0.03
1
Body weight upon arrival
2
Average of 2 consecutive day weights

P- value
0.93
0.89
0.95
0.91
0.32
0.76
0.67
0.60
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Table 3: Effect of Zelnate on percentage morbidity in high-risk, newly received beef calves.
Treatment
Item
Control
Zelnate
SEM
Morbidity, %
1st treatment1
49.9
56.5
0.04
2nd treatment1
23.6
18.3
0.04
3rd treatment1
6.0
1.5
0.2
Relapse2
47.4
32.2
0.6
Days till 1st treatment1
6.6
6.9
0.6
Days till 2nd treatment1
13.2
12.9
1.7
Days till 3rd treatment1
22.3
18.0
3.0
Serum haptoglobin levels d 03
14.1
13.9
0.3
Serum haptoglobin levels d 143
14.5
14.3
0.2
1 st
1 treatment = Enrofloxacin, 2nd treatment = Florfenicol, 3rd treatment = Ceftiofur
2
Relapse = number of calves retreated after 1st treatment
3
Units = ng/mL

P- value
0.31
0.37
0.12
0.09
0.72
0.91
0.41
0.40
0.99
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Table 4: Effect of Zelnate on rectal temperature and antibiotic usage cost in high-risk, newly received beef
calves.
Treatment
Item1
Control
Zelnate
SEM
P- value
Rectal Temperature, °C
1st treatment
40.6
40.6
0.1
0.74
2nd treatment
40.4
40.7
0.2
0.13
3rd treatment
40.5
40.3
0.3
0.71
Antibiotics
Antibiotic cost, $/calf
13.12
12.40
1.5
0.74
Antibiotics plus Zelnate, $/calf
13.12
22.36
1.5
<0.01
1 st
1 treatment = Enrofloxacin, 2nd treatment = Florfenicol, 3rd treatment = Ceftiofur, Antibiotic costs = cost to treat
calves, Antibiotics plus Zelnate = cost to treat calves in addition to Zelnate cost upon arrival

